Forecast: Healthcare Expenditure on Pharmaceuticals and Medical Non-Durable Goods in Sweden

The healthcare expenditure on pharmaceuticals and medical non-durable goods in Sweden has exhibited mixed trends over the past decade. From 2013 to 2023, the value fluctuated around 1.1% of GDP, peaking at 1.11 in 2016 and dipping to a low of 1.02 in 2028. Year-on-year variations indicate a generally volatile trend with both positive and negative shifts. Notably, 2020 saw the highest increase of 5.77%, likely due to the COVID-19 pandemic, followed by a 5.45% decline in 2021 as conditions stabilized. The five-year compound annual growth rate (CAGR) leading up to 2023 was -0.75%.

Looking ahead, the forecast suggests a gradual decline with a five-year CAGR of -0.39%, leading to a forecasted value of 1.02 by 2028. This indicates a slight, yet steady decrease in expenditure relative to GDP.

Future trends to watch for:

• Impact of technological advancements and new pharmaceutical developments.
• Government regulations and policies affecting healthcare funding.
• Demographic changes, particularly the aging population.
• Potential economic fluctuations and their effect on healthcare budgets.